40 / 140
162
17.Corbalán R, Nazzal C, Eggers G, et al. en representación del Grupo de
Angina Inestable, Departamento de Estudios Multicéntricos, Sociedad
Chilena de Cardiología y Cirugía Cardiovascular. Resultados del primer
registro chileno de angina inestable: características clínicas, perfil de
riesgo y tratamiento. Rev Med Chil. 2004 Feb; 132(2):135-43.
18.Neal B, MacMahon S, Chapman N; Blood Pressure Lowering
Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium
antagonists, and other blood-pressure-lowering drugs: results of
prospectively designed overviews of randomised trials. Blood Pressure
Lowering Treatment Trialists’ Collaboration. Lancet. 2000 Dec 9;
356(9246):1955-64.
19.Hajjari I, Kotchen T. Trends in prevalence, awareness, treatment, and
control of hypertension in the United States, 1988–2000. JAMA. 2003
Jul 9; 290(2):199-206.
20.Centers for Disease Control and Prevention (CDC). Vital signs:
prevalence, treatment, and control of hypertension—United States,
1999–2002 and 2005–2008. MMWR Morb Mortal Wkly Rep. 2011
Feb 4; 60(4):103-8. Accedido el 24 julio 2014.
21.Nazzal C, Campos P, Corbalán R, et al. En representación del Grupo
GEMI; Departamento de Estudios Multicéntricos, Sociedad Chilena
de Cardiología y Cirugía Cardiovascular. Impacto del plan AUGE
en el tratamiento de pacientes con infarto agudo al miocardio con
supradesnivel ST, en hospitales chilenos. Rev Med Chil. 2008 Oct;
136(10):1231-9.
22.Nazzal C, Lanas F, Garmendia ML, et al. Prevención secundaria post
infarto agudo de miocardio en hospitales públicos: implementación y
resultados de las garantías GES Rev Med Chil. 2013 Aug; 141(8):977-
86.
23.Garrido J, Chacón J, Sandoval D, et al. Control del Hipertenso, un
desafío no resuelto. Avances logrados en Chile mediante el Programa
de Salud Cardiovascular. Rev Chil Cardiol 2013; 32(2): 85-96.
24.Sandoval D, Bravo M, Koch E, et al. Overcoming barriers in the
management of hypertension: the experience of the cardiovascular
health program in chilean primary health care centers. Int J Hypertens.
2012;(2012):405892. doi: 10.1155/2012/405892. Epub 2012 Jun
4. Accedido el 24 julio 2014.
25.Lira MT, Kunstmann S, Caballero E, Guarda E, Villarroel L, Molina JC.
Prevención cardiovascular y actitud de cambio frente a los factores de
riesgo: un análisis crítico del estado actual. Rev Med Chil. 2006 Feb;
134(2):223-230.
26.Steptoe A, Doherty S, Rink E, Kerry S, Kendrick T, Hilton S. Behavioural
counseling in general practice for the promotion of healthy behaviour
among adults at increased risk of coronary heart disease: randomized
trial. BMJ. 1999 Oct 9;319(7215):943-7.
27.Fletcher BJ, Himmelfarb CD, Lira MT, Meininger JC, Pradhan SR,
Sikkema J. Global cardiovascular disease prevention: a call to action for
nursing: community-based and public health prevention initiatives. J
Cardiovasc Nurs. 2011 Jul-Aug;26(4 Suppl):S35-45.
28.Wood D, Kotseva K, Connolly S, et al. EUROACTION Study Group.Nurse-
coordinated multidisciplinary, family-based cardiovascular disease
prevention programme (EUROACTION) for patients with coronary heart
disease and asymptomatic individuals at high risk of cardiovascular
disease: a paired,cluster-randomised controlled trial. Lancet. 2008
Jun 14; 371(9629):1999-2012.
29.Lira MT, Rosales J, Ourcilleon A, et al. Estratificación de riesgo y
educación en prevención primaria: modificación de conductas a
mediano plazo en grupos de riesgo. Rev Chil Cardiol 2002; 21 (4): 295.
30.Kunstmann S, LiraMT, GaínzaD, De Gracia JA, Molina JC. Cardiovascular
disease prevention and risk factors control: Evaluation of educational
community level intervention and communicational strategies for
primary prevention. Circulation 2008 Vol 118 (12):e477.
31.Jorstad HT, von Birgelen C, Alings AM, et al. Effect of a nurse-
coordinated prevention programme on cardiovascular risk after an
acute coronary syndrome: main results of the RESPONSE randomised
trial. Heart. 2013 Oct; 99(19):1421-30.
32.Guarda E, Acevedo M, Lira MT, Chamorro G, Corbalán R. Insuficiente
control de factores de riesgo en prevención secundaria cardiovascular
Rev Méd Chile 2005; 133 (10): 1147-1152.
33.Lira MT. Educación incidental versus educación programada en
prevención secundaria de enfermedad coronaria Rev Chil Cardiol
2002; 21 (4):289.
34.Escobar C, Barrios V, Calderón A, et al. Diabetes mellitus en la población
hipertensa asistida en Atención Primaria en España. Grado de control
tensional y lipídico. Rev Clin Esp. 2007 May; 207(5):221-7.
35.López-Jaramillo P, Sánchez RA, Diaz M, et al. Latin America Expert
Group. Latin American consensus on hypertension in patients with
diabetes type 2 and metabolic syndrome. J Hypertens. 2013 Feb;
31(2):223-38.
36.Schargrodsky H, Hernández-Hernández R, Champagne BM, et al. for
the CARMELA study. CARMELA: assessment of the CV risk in seven Latin
American cities. Am J Med 2008; 121(1): 58-65.
37.Yusuf S, Islam S, Chow CK, et al. on behalf of the Prospective Urban
Rural Epidemiology (PURE) Study Investigators. Use of secondary
prevention drugs for cardiovascular disease in the community in high-
income, middle-income, and low-income countries (the PURE Study):
a prospective epidemiological survey. Lancet 2011; 378 (9798):
1231–43.
38.Lira MT, Kunstmann S, Caballero E, Gainza D, Molina JC. Waist
Circumference and its Association with Classic CV Risk Factors in
Healthy Women. Circulation 2008 Vol 118 (12):e465.
39.Grundy SM, Cleeman JI, Daniels SR, et al. on behalf of the American
Heart Association; National Heart, Lung, and Blood Institute. Diagnosis
and management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation. 2005 Oct 25; 112(17):2735-52.
40.Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association;
European Association for the Study of Diabetes. The metabolic
syndrome: time for a critical appraisal: joint statement from the
American Diabetes Association and the European Association for the
Study of Diabetes. Diabetes Care. 2005 Sep;28(9):2289-304.
41.Alberti KG, Eckel RH, Grundy SM, et al. on behalf of the International
Diabetes Federation Task Force on Epidemiology and Prevention;
Hational Heart, Lung, and Blood Institute; American Heart Association;
World Heart Federation; International Atherosclerosis Society;
International Association for the Study of Obesity. Harmonizing the
metabolic syndrome: a joint interim statement of the International
Diabetes Federation Task Force on Epidemiology and Prevention;
National Heart, Lung, and Blood Institute; American Heart Association;
[REV. MED. CLIN. CONDES - 2015; 26(2) 156-163]